Pharma Lobby Disputes Trump’s Claim That Drug Companies Are Negotiating
(Bloomberg) -- The pharmaceutical industry's leading lobby group said Tuesday it did not know of a meeting at the White House to discuss lowering prescription drug prices, after President Donald Trump said executives were coming in this week to negotiate.
“We are not aware of any meeting,” said Nicole Longo, a spokeswoman for Pharmaceutical Research and Manufacturers of America.
Trump told reporters before departing to Kenosha, Wisconsin that drug companies were coming in to see him “this week” to broker a deal “substantially” reducing drug prices. White House officials subsequently declined to comment when asked when the meeting is scheduled and who would participate.
“We're working on drug companies on substantially lowering drug prices,” Trump said. “I've put out a favored nations clause, I've signed it. That means we get the lowest prices anywhere in the world, and we match whoever gets the lost and the drug companies are having a real problem with that and they are coming in to see me, and we expect to get a very substantial price reduction of prescription drugs which has never been done before.”
Trump has previously claimed drug executives were ready to negotiate over his “favored nations” executive order, which purports to require drugmakers to sell medicines in the U.S. at prices comparable to those in countries with more stringent price controls.
Trump signed the order in late July, saying he would give drug companies a month to negotiate a less severe deal before it took effect and that he planned to meet with executives the following week.
The order hasn't been published and no meeting has happened. The industry instead is running an advertising campaign criticizing Trump's proposal.
The president, though, has repeatedly boasted of the executive order as if it was a done deal, including during remarks to the Republican National Convention last week. The White House has refused to release the actual text of the executive order.
“I did a favored nations clause, meaning we pay the same price as the lowest country that has the best deal, the companies are going crazy, the drug companies,” Trump told convention delegates last Monday in Charlotte, North Carolina.
Drug makers did provide the White House with a counterproposal to avert the favored nations executive order last week, according to Politico. The plan reportedly would cut prices for a narrow slice of medicines -- physician-administered drugs paid for by Medicare Part B -- by 10 percent.
That's about a third of the cuts that might be realized if prices were fully pegged to international rates.
It is expected that if the administration does push forward on Trump's executive order it could involve months of rulemaking at various federal agencies.
The order is also expected to be limited in scope, applying only to drugs administered at a doctor's office, not prescriptions filled at an outside pharmacy by consumers. Still, the effort has unleashed a fierce lobbying effort by the pharmaceutical industry.
Trump has taken notice of the advertisements and now frequently mentions them during campaign events, saying they are evidence that his efforts are impactful. And the president's campaign has begun airing television ads of its own, labeling Democratic nominee Joe Biden as the drug industry's preferred candidate.
“When you see a commercial where drug companies are taking commercials against your president, President Trump, that's me, the only reason they're fighting me is because I instituted very strong reforms,” Trump told supporters during a North Carolina tele-rally earlier this month.
©2020 Bloomberg L.P.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.